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Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization
A Systematic Review and Meta-analysis
Todd C. Lee, MD, MPH; Simone Vigod, MD, MSc; Émilie Bortolussi-Courval, BScN; Ryan Hanula, BSc; David R. Boulware, MD, MPH; Eric J. Lenze, MD;
Angela M. Reiersen, MD, MPE; Emily G. McDonald, MD, MSc

Abstract

Key Points

IMPORTANCE Widely available and affordable options for the outpatient management of COVID-19
are needed, particularly for therapies that prevent hospitalization.

Question Is early administration of
fluvoxamine associated with
hospitalization in symptomatic adult

OBJECTIVE To perform a meta-analysis of the available randomized clinical trial evidence for

outpatients with confirmed COVID-19?
Findings In this systematic review and

fluvoxamine in the outpatient management of COVID-19.

bayesian meta-analysis of 3 clinical trials,

DATA SOURCES World Health Organization International Clinical Trials Registry Platform and

which accounted for varying prior

ClinicalTrials.gov.

probabilities coupled with a frequentist
sensitivity analysis, there was a high

STUDY SELECTION Studies with completed outpatient trials with available results that compared

probability (94.1%-98.6%) that

fluvoxamine with placebo were included.

fluvoxamine was associated with a
reduced risk for hospitalization, with a

DATA EXTRACTION AND SYNTHESIS The PRISMA 2020 guidelines were followed and study

frequentist risk ratio of 0.75 (95% CI,

details in terms of inclusion criteria, trial demographics, and the prespecified outcome of all-cause

0.58-0.97).

hospitalization were extracted. Risk of bias was assessed by the Cochrane Risk of Bias 2 tool and a
bayesian random effects meta-analysis with different estimates of prior probability was conducted:
a weakly neutral prior (50% chance of efficacy with 95% CI for risk ratio [RR] between 0.5 and 2.0)
and a moderately optimistic prior (85% chance of efficacy). A frequentist random-effects metaanalysis was conducted as a senstivity analysis, and the results were contextualized by estimating the
probability of any association (RR ⱕ 1) and moderate association (RR ⱕ 0.9) with reduced
hospitalization.

Meaning These findings suggest that
fluvoxamine, a widely available and
inexpensive treatment for outpatients
with COVID-19, was associated with a
reduction in hospitalizations.

+ Supplemental content

MAIN OUTCOMES AND MEASURES All-cause hospitalization.

Author affiliations and article information are
listed at the end of this article.

RESULTS This systematic review and meta-analysis of 3 randomized clinical trials and included 2196
participants. The RRs for hospitalization were 0.78 (95% CI, 0.58-1.08) for the bayesian weakly
neutral prior, 0.73 (95% CI, 0.53-1.01) for the bayesian moderately optimistic prior, and 0.75 (95% CI,
0.58-0.97) for the frequentist analysis. Depending on the scenario, the probability of any association
with reduced hospitalization ranged from 94.1% to 98.6%, and the probability of moderate
association ranged from 81.6% to 91.8%.
CONCLUSIONS AND RELEVANCE In this systematic review and meta-analysis of data from 3 trials,
under a variety of assumptions, fluvoxamine showed a high probability of being associated with
reduced hospitalization in outpatients with COVID-19. Ongoing randomized trials are important to
evaluate alternative doses, explore the effectiveness in vaccinated patients, and provide further
refinement to these estimates. Meanwhile, fluvoxamine could be recommended as a management
(continued)
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Abstract (continued)

option, particularly in resource-limited settings or for individuals without access to SARS-CoV-2
monoclonal antibody therapy or direct antivirals.
JAMA Network Open. 2022;5(4):e226269. doi:10.1001/jamanetworkopen.2022.6269

Introduction
Finding effective outpatient therapies for COVID-19 has been a major research undertaking since the
beginning of the pandemic. While therapies, such as direct antivirals and engineered monoclonal
antibodies, represent the current state-of-the art, there are challenges with availability, access,
administration, and affordability in most areas of the world. Drug repurposing, or the use of presently
available and affordable medications for the management of COVID-19 is an area of substantial
ongoing research interest. The first medication to gain international interest for repurposing was
hydroxychloroquine; however, it was demonstrated to be ineffective in randomized controlled trials.1
A variety of other candidate molecules have been the subject of randomized controlled trials with
varying success.2
One such medication is fluvoxamine, which is a selective serotonin reuptake inhibitor (SSRI)
that is also a potent activator of the sigma-1 receptor3 which decreases inflammation via reducing
endoplasmic reticulum stress.4 In a murine sepsis model, fluvoxamine administration reduced
mortality predominantly through sigma-1 activation.5 On this preclinical basis, the phase 2 STOP
COVID 1 trial was conducted.6 This 152 patient double-blind, randomized placebo-control trial found
fluvoxamine effective at preventing progression to severe COVID-19 defined as hypoxemia with
dyspnea or hospital admission. Shortly thereafter, a benefit in preventing hospitalization or death
was also reported in an uncontrolled 113-person prospective cohort.7 Later, an association with
survival in COVID-19 for users of fluvoxamine was identified in a multicenter retrospective
cohort study.8
Two larger phase 3 trials have been subsequently completed: the STOP COVID 2 trial in the US
and Canada9 and the TOGETHER trial in Brazil10 Both trials were presented to the US National
Institutes of Health in August 2021. The STOP COVID 2 trial was stopped for futility in May 2021 after
an interim analysis found that the low event rate seen in the trial was associated with a less than 10%
conditional probability of demonstrating efficacy within an attainable sample size based on
recruitment rate.11 The TOGETHER trial, which had a higher primary outcome event rate, was
stopped after demonstrating clinical benefit.10 We conducted a systematic review and meta-analysis
of outpatient fluvoxamine trials to contextualize the evidence regarding hospitalization to inform
clinical decision making, policy, and guidelines.

Methods
This systematic review and meta-analysis is reported according to Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) 2020 reporting guideline.12 Study details in terms
of inclusion criteria, trial demographics, and the prespecified outcome of all-cause hospitalization
were extracted.

Search Strategy, Study Selection, Data Extraction, and Assessment of Bias
On November 12, 2021, we searched the World Health Organization International Clinical Trials
Registry Platform and ClinicalTrials.gov for all registered clinical trials of fluvoxamine for the
treatment of patients with COVID-19. Two independent reviewers screened results for eligibility,
which included completed studies of outpatients comparing fluvoxamine to placebo or standard of

JAMA Network Open. 2022;5(4):e226269. doi:10.1001/jamanetworkopen.2022.6269 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 11/16/2022

April 6, 2022

2/10

JAMA Network Open | Infectious Diseases

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization

care. Studies with published or publicly presented data (with the authors’ permission) were selected
for inclusion.
For included studies, we summarized study inclusion criteria and patient demographics. We
selected all-cause hospitalization as the primary outcome of interest given the implications for health
care resource use. Two reviewers extracted hospitalization outcome data in each treatment group
and these numbers were subsequently verified with the study principal investigators by email. For
the TOGETHER trial, the published primary outcome included hospitalization or emergency
department observation lasting 6 hours or more. To arrive at a more homogeneous outcome, we
contacted the TOGETHER trial authors and obtained outcome data on emergency department visits
lasting more than 24 hours and used this as a more representative proxy for hospital admission than
an ED visit alone. For the STOP COVID 2 trial, we obtained demographic and outcomes data directly
from the principal investigators (EJL and AMR) based on their presentation to the National Institutes
of Health.11 We only included intention-to-treat analyses even if per protocol analyses suggested
larger effect sizes were possible. Two independent reviewers assessed each study for bias using the
Cochrane risk-of-bias 2 tool for randomized trials.

Statistical Analysis
We conducted 2 analyses with a bayesian random effects meta-analysis on the log RR scale using the
bayesmeta13 and metafor14 packages in R version 4.1.1 (eMethods in the Supplement).15 We selected
priors based on 2 estimates of how promising the pre-existing data were. Scenario 1 used a weakly
informative neutral prior, given that most treatments in medicine have a RR (RR) between 0.5 and 2
and because the STOP COVID 2 trial results were neutral (with a population mean [μ] [SD] of 0
[0.355]) on the log RR scale, this corresponds to a 50% chance of efficacy with 95% probability that
the RR would be between 0.5 and 2).16 Scenario 2 used a moderately optimistic prior given the
positive results of the STOP COVID 1 trial and the prospective cohort (with a μ [SD] of −0.41 [0.4],
which corresponds to a 85% chance the RR would be ⱕ1).16 In both scenarios, the prior for the
heterogeneity parameter (τ) used a half-Cauchy distribution with scale 0.10, which is the mean
heterogeneity for meta-analyses of trials using hospitalization outcomes.17 As a sensitivity analysis,
we also conducted a frequentist restricted maximum likelihood (REML) random effects metaanalysis on the log RR scale using the metan18 module for STATA version 17 (StataCorp). Results were
exponentiated to the RR scale for presentation.
Using the estimated RRs from the above analyses as the mean and their associated 95% CIs to
calculate standard errors, we then simulated 100 000 trials in STATA version 17 (StataCorp) on the
log scale. We generated a representative probability density function on the RR scale using kernel
density estimation and graphed it with the relevant prior probabilities. We then estimated the
probabilities of any association (RR < 1) and moderate association (RR ⱕ 0.9) by integrating the area
under the curves (eMethods in the Supplement).19 Given the low cost of fluvoxamine and decades
of established safety, we decided in advance that a moderate association would correlate to an
absolute risk reduction between 0.5% and 1% assuming a 5% to 10% baseline risk of hospitalization,
as observed in the control groups of several outpatient clinical trials. For context, this corresponds
to a number needed to treat of 100 patients to 200 patients. Two independent reviewers assessed
the certainty of evidence for hospitalization using GRADE methods (Grading of Recommendations,
Assessment, Development and Evaluations).20

Results
The initial search yielded 19 candidate randomized controlled trials and 10 were retained following
removal of duplicates (Figure 1; eTable 1 in the Supplement). Seven studies were then excluded for
the following reasons: 4 studies because they were still recruiting participants,21-24 1 study because it
recruited only inpatients,25 1 study because it was suspended without results,26 and 1 study was
excluded because it was not yet recruiting.27
JAMA Network Open. 2022;5(4):e226269. doi:10.1001/jamanetworkopen.2022.6269 (Reprinted)
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Included Studies
The remaining 3 trials (STOP COVID 1 trial [N = 152],6 STOP COVID 2 trial [N = 547], and TOGETHER
trial [N = 1497])10 included a total of 2196 analyzed patients (Table 1). It should be noted that
because of its sample size, the TOGETHER trial is heavily weighted in the results of analyses. All 3
were placebo-controlled randomized controlled trials that recruited unvaccinated, symptomatic
adults with microbiologically confirmed SARS-CoV-2 infection who were within 6 to 7 days of
infection and not requiring oxygen. Whereas the STOP COVID 1 trial took all patients, the STOP COVID
2 and TOGETHER trials enriched their population for at least 1 at-risk feature for deterioration.
Overall, the median age of participants was between 46 and 50, 55% to 72% of participants were
female, 44% to 56% were obese. Most patients in the STOP COVID trials self-reported being White
individuals; in the TOGETHER trial, 96% self-reported as being multiracial individuals. No trials
included vaccinated patients and all trials predated both the Delta and Omicron variants. The risk of
bias was considered low for all trials by both reviewers.

Figure 1. PRISMA Flow Diagram of Included Studies
19 Records identified
11 WHO International
Clinical Trials Registry
8 ClinicalTrials.gov
9 Records removed before screening
8 Duplicate records
1 Clear database error
10 Records screened
1 Record excluded (not outpatients)
9 Reports sought for retrieval
6 Reports not retrieved
4 Ongoing recruitment
1 Suspended not reported
1 Not started
3 Reports assessed for eligibility
3 Studies included in review
2 Reports of included studies

Table 1. Fluvoxamine COVID-19 Trial Details
Source

Dates

Original outcome

Inclusion criteria

Demographics

Stop COVID 16
United States

April 10, 2020August 5, 2020

Clinical deterioration:
Hospitalization or new
hypoxemia within 15 d

Age ≥18 unvaccinated
positive test with: ≤7 d
symptoms

Median age 46; 72% female; 70% White
individuals; 56% BMI ≥ 30; 20%
hypertension; 11% diabetes

Stop COVID 29
United States and
Canada

December 22,
2020-May 21,
2020

Clinical deterioration:
Hospitalization or new
hypoxemia within 15 d

Age ≥30 unvaccinated
positive test with: ≤6 d
symptoms

Median age 47; 62% female; 73% White
individuals; 44% BMI ≥ 30; 21%
hypertension; 9% diabetes

Criterion for high risk

Median 5 d of symptoms

TOGETHER10
Brazil

January 20,
2021-August 5,
2021

ED visit ≥6 h or
hospitalization within 28 d

Age ≥18 unvaccinated
positive test with: ≤7 d
symptoms

Median age 50; 55% female; 96% mixed
race; 51% BMI ≥ 30; 13% hypertension;
16% diabetes

Criterion for high risk

Mean 3.8 d of symptomsb

Fluvoxamine
target dosea

Duration, d

100 mg

15

100 mg

15

100 mg

10

Median 4 d of symptoms

Abbreviations: BMI, body mass index; ED, emergency department.
a

b

Median not provided; missing data on approximately 23% of participants.

Target dose was to be taken orally twice a day.
JAMA Network Open. 2022;5(4):e226269. doi:10.1001/jamanetworkopen.2022.6269 (Reprinted)
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Meta-analysis
In the bayesian analyses, the pooled RR in favor of fluvoxamine was 0.78 (95% CI, 0.58-1.08) for the
weakly neutral prior and 0.73 (95% CI, 0.53-1.01) for the moderately optimistic prior (Table 2;
eFigures 1 and 2 in the Supplement). In the frequentist meta-analysis, the pooled RR in favor of
fluvoxamine was 0.75 (95% CI, 0.58-0.97; I2, 0.2%) (Figure 2). The overall probability of association
with reduced hospitalization ranged from 94.1% to 98.6%, and of moderate association ranged from
81.6% to 91.8% (Table 2 and Figure 3). Statistical code needed to reproduce the analysis is included
in the eMethods in the Supplement.

GRADE Certainty of Evidence
We felt the certainty of the evidence was moderate. Although all 3 trials were placebo-controlled
randomized trials, there were some inconsistent findings given the STOP COVID 2 trial was
terminated for futility. Although there was some risk of bias in the TOGETHER trial, we attempted to
address this by limiting the primary outcome to emergency department visits that were 24 hours or
longer, thus removing some concerns about the validity of shorter visits (6 to 24 hours in length). A
moderate strength recommendation in favor of fluvoxamine could be considered in certain clinical
scenarios as detailed in the discussion. According to the GRADE methods, such a recommendation is
reasonable when shared decision-making is expected. Weaker recommendations usually apply when
risks start to approach the benefits, or when significant resources are required for the intervention,
neither of which is the case for fluvoxamine.

Discussion
Based on currently available clinical trial data, we demonstrate high probability of an association
between fluvoxamine and at least a moderate reduction in COVID-19 hospitalizations, under a variety
of assumptions. By comparison, outpatient trials with hydroxychloroquine1 and ivermectin28 have
not shown any efficacy and yet these agents continue to be prescribed. Further data from the
ongoing identified studies such as the COVID-Out trial (NCT04510194) and the ACTIV-6 trial
(NCT04885530) will help refine these estimates. Of note, both of these trials are using 50 mg twice
daily of fluvoxamine, which, if unsuccessful, could indicate that 100 mg twice daily is the minimum
effective dose. Recently, despite the results of the STOP COVID 1 trial and the TOGETHER trial, the
Infectious Diseases Society of America recommended against the use of fluvoxamine, with the
exception of use in clinical trial settings.29 Based on our analysis, and coupled with worldwide
accessibility, decades of safety data, and a current price of approximately $1 per day,30,31

Table 2. Meta-analysis Results
Probability, %
Scenario

Pooled RR (95% CI)

RR < 1

RR ≤ 0.9

Weakly neutral

0.78 (0.58-1.08)

94.1

81.6

Moderately optimistic

0.73 (0.53-1.01)

97.2

89.9

Frequentist analysis

0.75 (0.58-0.97)

98.6

91.8

Abbreviation: RR, risk ratio.

Figure 2. Frequentist Random Effects Meta-analysis
Favors
fluvoxamine

Favors
placebo

Study

Fluvoxamine
No./total No.

Control
No./total No.

RR
(95% CI)

STOP COVID 1

1/80

5/72

0.18 (0.02-1.50)

1.51

STOP COVID 2

11/272

12/275

0.93 (0.42-2.06)

10.59

Together

76/741

104/756

0.75 (0.56-0.98)

87.91

Overall REML: I 2 = 0.2%, P = .37

88/1093

121/1103

0.75 (0.58-0.97)
0.2

Weight,
%

100
1

4

RR (95% CI)
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fluvoxamine may be a reasonable option for high-risk outpatients who do not have access to
SARS-CoV-2 monoclonal antibodies, direct antivirals, or clinical trials. Even at a number to treat of
200 patients (absolute risk reduction, 0.5%), the corresponding cost to prevent admission would
only be $2800. Clinicians who prescribe fluvoxamine for COVID-19 should familiarize themselves

Figure 3. Probability Densities of the Primary and Sensitivity Analyses
A Weak neutral prior

4
Probability that RR ≤0.9 (81.6%)
Prior probability
Meta-analytic posterior probability

Probability density

3

2

1

0
0

0.25

0.50

0.75

1

1.25

1.50

1

1.25

1.50

1

1.25

1.50

RR
B

Moderately optimistic prior
4
Probability that RR ≤0.9 (89.9%)
Prior probability
Meta-analytic posterior probability

Probability density

3

2

1

0
0

0.25

0.50

0.75

RR
C

Frequentist analysis
4
Probability that RR ≤0.9 (91.8%)
Meta-analytic probability

Probability density

3

2

1

0
0

0.25

0.50

0.75

RR
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with relative contraindications and notable drug-drug interactions, including the need to limit
caffeine (eTable 2 in the Supplement). The most common reported side effects from fluvoxamine in
clinical trials are gastrointestinal (nausea, vomiting, diarrhea, and anorexia) and central nervous
system complaints (headache, dizziness, somnolence, and nervousness).
Strengths of our analysis are the use of all available data and consistency of results by both a
bayesian approach with multiple prior probability estimates and a classic random effects metaanalysis. For all analyses, we quantified the overall probability of any association and a moderate
association of fluvoxamine with reduced hospitalization to help with decision-making. Further, we
restricted the TOGETHER trial emergency department visits to those longer than 24 hours to address
concerns29 about whether a 6-hour visit is an accurate proxy for health care use or marker of clinical
deterioration. We used the intention-to-treat analysis, reflecting the reality of physician prescribing.
In the TOGETHER trial, results were better in the per-protocol analysis.10

Limitations
This review had limitations, including variability in health care practices, resource availability, and
circulating variants between trials, leading to differences in the baseline event rates and the
associated absolute risk reduction. While we have attempted to correct for subjectivity by limiting
this analysis to hospitalizations, the decision to hospitalize may vary between geographic areas and
even time points based on systemic burdens on the health care system. Nonetheless, all-cause
hospitalization is the most common important outcome of outpatient COVID-19 trials because ICU
admission or death would require prohibitively large studies. Additionally, all 3 trials excluded fully
vaccinated individuals, whose rates of hospitalization are greatly reduced, and therefore any
estimates of absolute effect size would likely be an overestimate in vaccinated patients. Another
limitation is the inclusion of only 3 trials to date and the TOGETHER trial contributed between 66%
and 88% of the analytic weight. Using a living systematic review approach will address this clinical
question and incorporate emerging evidence.

Conclusions
In this systematic review and meta-analysis of data from 3 trials, under a variety of assumptions, we
found the probability that fluvoxamine was associated with reduced hospitalization ranged from
94.1% to 98.6% and the probability of moderate association ranged from 81.6% to 91.8%. Ongoing
randomized controlled trials of fluvoxamine should continue, particularly those studying lower
50-mg doses (which may be better tolerated), evaluating efficacy in vaccinated individuals, or
studying the related SSRI fluoxetine, which is on the World Health Organization’s list of essential
medications. In the meantime, fluvoxamine is an immediately available, safe, and inexpensive
management option with a high probability of moderate efficacy. It could be recommended as a
treatment option for patients without contraindication, particularly in resource-limited settings or for
individuals without access to monoclonal antibodies or direct antivirals.
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